Telomir Pharmaceuticals, Inc. Operating Income
Telomir Pharmaceuticals, Inc. (TELO) reported Operating Income of $2.19 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2025-05-14
- Telomir Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-03-31 was $2.19M, a 14.19% increase year-over-year.
- Telomir Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2024-03-31 was $1.92M.
| Period end | Operating Income (Loss) 3 month |
|---|---|
| 2025-03-31 | $2.19M 10-Q · filed 2025-05-14 |
| 2024-03-31 | $1.92M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |